PharmAla Biotech forms joint venture for APA-01 drug development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
May 13, 2026 8:30 AM EDTTORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (PharmAla or the Company), a leader in the research, development, and manufacturing of clinical-grade MDMA and novel MDXX-class compounds, today announced that it has executed a definitive SPV Formation, Shareholder and License Agreement (the Definitive Agreement) with Aluvaris Inc. (Aluvaris) and Diteba Inc. (Diteba). The Definitive Agreement establishes a jointly-owned special purpose vehicle called Restora Neurosciences (the Restora or the... More
